Evidence map›Paper›PMID 38294307›Full record

ArticleRadiology. Artificial intelligence2024

Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.

Olivia Prior, Carlos Macarro, Víctor Navarro, Camilo Monreal, Marta Ligero, Alonso Garcia-Ruiz, Garazi Serna, Sara Simonetti, Irene Braña, Maria Vieito and 10 more

Erratum issuedAbstract read
In one paragraph

Article in Radiology. Artificial intelligence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Olivia PriorFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0009-0000-4913-6716
Carlos MacarroFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0009-0000-0597-9316
Víctor NavarroFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0001-6925-4605
Camilo MonrealFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0009-0001-1025-0770
Marta LigeroFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0001-9824-7316
Alonso Garcia-RuizFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0003-0129-3020
Garazi SernaFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).
Sara SimonettiFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).
Irene BrañaFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).
Maria VieitoFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).
Manuel EscobarFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0002-3794-2224
Jaume CapdevilaFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).
Annette T ByrneFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).
Rodrigo DienstmannFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0001-5997-318X
Rodrigo ToledoFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0003-3070-6795
Paolo NuciforoFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0003-1380-0990
Elena GarraldaFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0002-4412-7842
Francesco GrussuFrom the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0002-0945-3909
Kinga Bernatowicz *From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0001-9166-1709
Raquel Perez-Lopez *From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).ORCID 0000-0002-9176-0130

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose To identify precise three-dimensional radiomics features in CT images that enable computation of stable and biologically meaningful habitats with machine learning for cancer heterogeneity assessment. Materials and Methods This retrospective study included 2436 liver or lung lesions from 605 CT scans (November 2010-December 2021) in 331 patients with cancer (mean age, 64.5 years ± 10.1 [SD]; 185 male patients). Three-dimensional radiomics were computed from original and perturbed (simulated retest) images with different combinations of feature computation kernel radius and bin size. The lower 95% confidence limit (LCL) of the intraclass correlation coefficient (ICC) was used to measure repeatability and reproducibility. Precise features were identified by combining repeatability and reproducibility results (LCL of ICC ≥ 0.50). Habitats were obtained with Gaussian mixture models in original and perturbed data using precise radiomics features and compared with habitats obtained using all features. The Dice similarity coefficient (DSC) was used to assess habitat stability. Biologic correlates of CT habitats were explored in a case study, with a cohort of 13 patients with CT, multiparametric MRI, and tumor biopsies. Results Three-dimensional radiomics showed poor repeatability (LCL of ICC: median [IQR], 0.442 [0.312-0.516]) and poor reproducibility against kernel radius (LCL of ICC: median [IQR], 0.440 [0.33-0.526]) but excellent reproducibility against bin size (LCL of ICC: median [IQR], 0.929 [0.853-0.988]). Twenty-six radiomics features were precise, differing in lung and liver lesions. Habitats obtained with precise features (DSC: median [IQR], 0.601 [0.494-0.712] and 0.651 [0.52-0.784] for lung and liver lesions, respectively) were more stable than those obtained with all features (DSC: median [IQR], 0.532 [0.424-0.637] and 0.587 [0.465-0.703] for lung and liver lesions, respectively;

Indexed as

Liver NeoplasmsLung NeoplasmsHumansMachine LearningMaleMiddle AgedRadiomicsReproducibility of ResultsRetrospective StudiesTomography, X-Ray ComputedCTDiffusion-weighted ImagingDynamic Contrast-enhanced MRILiverLungMRIOncologyRadiomicsUnsupervised Learning

Identifiers

PMID38294307
PMCPMC10982821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.